GSK Acquires Chimagen's Tech for $750M | Pharma and Biotech Daily
Wednesday, September 16, 2026
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant strides and strategic maneuvers reshaping the landscape of healthcare and drug development.
Kicking things off, GlaxoSmithKline (GSK) has made headlines with its acquisition of Chimagen Biosciences' trispecific T cell engager technology, targeting multiple myeloma. This move, valued at up to $750 million, highlights GSK's strategic focus on expanding its oncology pipeline through cutting-edge immunotherapeutic approaches. Trispecific T cell engagers are an emerging class of biologics that bind to three different targets simultaneously, effectively arming the immune system to recognize and destroy cancer cells more efficiently. This acquisition not only strengthens GSK's position in the competitive oncology market but also addresses a significant need for more effective multiple myeloma treatments.
In parallel, Curium has achieved a notable milestone with the FDA approval of Bexlutry, a radioligand therapy for gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This therapy utilizes radioactive isotopes attached to molecules that specifically target cancer cells, delivering radiation directly while minimizing harm to healthy tissue. The approval of Bexlutry is a crucial development in oncologic care, expanding treatment options for patients dealing with complex and heterogeneous tumors. It underscores the growing role of targeted radiotherapies in providing precision medicine solutions.
On the financial front, Electra Therapeutics is gearing up for an initial public offering (IPO) to raise $325 million. The proceeds are intended to advance its late-stage clinical trials for severe hemophagocytic lymphohistiocytosis (SHLH), a rare autoimmune condition. This move reflects a broader trend among biotech companies turning to public markets to support niche therapeutic areas with high unmet needs and potential orphan drug status benefits.
Turning to clinical advancements, Corbus Pharmaceuticals has reported encouraging Phase 1b data for CRB-913, which employs CB1 inverse agonism in combating obesity. By modulating endocannabinoid activity linked to appetite and energy balance, this approach offers a promising direction for managing metabolic disorders. Simultaneously, CSL Seqirus has shared Phase 3 results showcasing the superior efficacy of its MF59-adjuvanted cell-based quadrivalent influenza vaccine in older adults, highlighting ongoing innovations in vaccine technologies tailored for vulnerable populations.
The FDA's regulatory landscape is also evolving with the launch of Operation Trialblazer. This initiative seeks to streamline early-phase U.S. clinical trials through expedited IND application processes, facilitating faster transitions from research to clinical applications and fostering innovation by reducing bureaucratic hurdles. Meanwhile, the FDA is preparing for potential psychedelic medicine approvals, ensuring robust oversight frameworks are in place as these therapies near market availability.
Yet, as always in drug development, challenges persist. Novo Nordisk's decision to terminate its GLP-1 obesity drug partnership with Ascendis following unsatisfactory results exemplifies the inherent risks even promising preclinical data can present. Similarly, setbacks faced by Axoltis Pharma and Eli Lilly with their neurological and metabolic candidates reinforce the complexities of translating scientific hypotheses into viable therapies.
Sanofi has taken significant strategic steps as well by divesting 20 older medicines and three manufacturing sites to Cheplapharm. This decision aligns with Sanofi's focus on innovation under CEO Paul Hudson’s leadership and allows the company to reallocate resources towards groundbreaking therapies.
In diagnostic advances, the FDA’s approval of Telix's Pixclara marks a breakthrough for brain cancer imaging. Being the first FET-PET imaging drug approved for gliomas, Pixclara could significantly enhance diagnostic accuracy and treatment planning for these challenging tumors.
These developments underscore a transformative period where scientific innovation is paired with strategic regulatory adjustments to navigate complex market dynamics. As companies continue adapting to these changes, their ability to innovate while addressing safety and efficacy concerns will be critical in advancing therapeutic frontiers and improving patient outcomes across diverse medical landscapes. As always, we’ll be here at Pharma Daily to keep you informed on these pivotal changes shaping our industry’s future.
Thank you for tuning into today’s episode of Pharma Daily. Keep innovating and stay informed!